264 related articles for article (PubMed ID: 18563057)
41. [Pharmacoeconomics of asthma].
Jahnz-Rózyk K; Targowski T
Pol Merkur Lekarski; 2004 May; 16 Suppl 1():48-9. PubMed ID: 15524016
[TBL] [Abstract][Full Text] [Related]
42. Perspectives on the pharmaceutical industry.
Reinhardt UE
Health Aff (Millwood); 2001; 20(5):136-49. PubMed ID: 11558698
[TBL] [Abstract][Full Text] [Related]
43. When will the U.S. flinch at cancer drug prices?
Vanchieri C
J Natl Cancer Inst; 2005 May; 97(9):624-6. PubMed ID: 15870428
[No Abstract] [Full Text] [Related]
44. [Application of pharmacoeconomics in clinical management].
Amat Díaz M; Poveda Andrés JL; Carrera-Hueso FJ
Farm Hosp; 2011 May; 35 Suppl 2():18-24. PubMed ID: 22445505
[TBL] [Abstract][Full Text] [Related]
45. Proposal To Use VA Price As a Benchmark Is off the Mark.
Kirkner RM
Manag Care; 2016 Dec; 25(12):14-15. PubMed ID: 28121548
[TBL] [Abstract][Full Text] [Related]
46. What's in a perspective?
Glick HA
Value Health; 2010; 13(1):2. PubMed ID: 19912594
[No Abstract] [Full Text] [Related]
47. Is there a role for pharmacoeconomics in developing countries?
Harper JR
Pharmacoeconomics; 2011 May; 29(5):435-6; author reply 436-7. PubMed ID: 21504243
[No Abstract] [Full Text] [Related]
48. The FDA and regulation of cost-effectiveness claims.
Neumann PJ; Zinner DE; Paltiel AD
Health Aff (Millwood); 1996; 15(3):54-71. PubMed ID: 8854508
[TBL] [Abstract][Full Text] [Related]
49. [Pharmacoeconomics. Potent drugs, diseases are costly].
Flaten O
Tidsskr Nor Laegeforen; 1994 Apr; 114(11):1345-6. PubMed ID: 8079219
[No Abstract] [Full Text] [Related]
50. Exploring the rise in American pharmaceutical prices.
Marwaha A
Pharos Alpha Omega Alpha Honor Med Soc; 2002; 65(2):11-5. PubMed ID: 12099112
[No Abstract] [Full Text] [Related]
51. Costs, innovation and efficiency in anti-infective therapy.
Bootman JL; Milne RJ
Pharmacoeconomics; 1996; 9 Suppl 1():31-9. PubMed ID: 10160114
[TBL] [Abstract][Full Text] [Related]
52. Differential pricing of new pharmaceuticals in lower income European countries.
Kaló Z; Annemans L; Garrison LP
Expert Rev Pharmacoecon Outcomes Res; 2013 Dec; 13(6):735-41. PubMed ID: 24219049
[TBL] [Abstract][Full Text] [Related]
53. Strategic planning for applied pharmacoeconomics programs.
Wanke LA; Ryan GM
Pharm Pract Manag Q; 1996 Jan; 15(4):64-74. PubMed ID: 10153846
[TBL] [Abstract][Full Text] [Related]
54. [Economical evaluation of drugs. A steering method for the pharmaceutical sector of the 1990's?].
Grund J; Husbyn H
Tidsskr Nor Laegeforen; 1994 Mar; 114(8):947-50. PubMed ID: 8191475
[TBL] [Abstract][Full Text] [Related]
55. American pharmaceutical prices.
Alagona P
Pharos Alpha Omega Alpha Honor Med Soc; 2002; 65(4):58. PubMed ID: 12592980
[No Abstract] [Full Text] [Related]
56. Do pharmaceutical prices respond to potential patient out-of-pocket expenses?
Pavenik N
Rand J Econ; 2002; 33(3):469-87. PubMed ID: 12585303
[TBL] [Abstract][Full Text] [Related]
57. Pharmacoeconomics: historical perspective.
Bootman JL; McGhan WF; Townsend RJ
Ann Pharmacother; 2006 Mar; 40(3):518-9. PubMed ID: 16478813
[No Abstract] [Full Text] [Related]
58. Paying the piper for pharmacoeconomic studies.
Neumann PJ
Med Decis Making; 1998; 18(2 Suppl):S23-6. PubMed ID: 9566464
[No Abstract] [Full Text] [Related]
59. [Pharmacoeconomics and cost of cancer drugs].
Camps Herrero C; Caballero Díaz C; Blasco Cordellat A
Farm Hosp; 2010 Mar; 34 Suppl 1():12-5. PubMed ID: 20920852
[TBL] [Abstract][Full Text] [Related]
60. [Discount for only one drug of the same group leads to impaired health care quality].
Bergström R
Lakartidningen; 2006 Feb 8-14; 103(6):387-8; discussion 388. PubMed ID: 16536044
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
